Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin- 2(1H)-one HIV integrase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2754-2761

  Boros, Eric E ^a   Edwards, Cynthia E ^a   Foster, Scott A ^a   Fuji, Masahiro ^b   Fujiwara, Tamio ^b   Garvey, Edward P ^a   Golden, Pamela L ^a   Hazen, Richard J ^a   Jeffrey, Jerry L ^a   Johns, Brian A ^a   Kawasuji, Takashi ^b   Kiyama, Ryuichi ^b   Koble, Cecilia S ^a   Kurose, Noriyuki ^b   Miller, Wayne H ^a   Mote, Angela L ^a   Murai, Hitoshi ^b   Sato, Akihiko ^b   Thompson, James B ^a   Woodward, Mark C ^a   Yoshinaga, Tomokazu ^b   more..

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 7 [(4 FLUOROPHENYL)METHYL] 4 HYDROXY 1 METHYL N [2 (METHOXY)ETHYL] 2 OXO 1,2 DIHYDRO 1,5 NAPHTHYRIDIN 3 CARBOXAMIDE; 7 BENZYL 4 HYDROXY 1,5 NAPHTHYRIDIN 2(1H) ONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE; INTEGRASE INHIBITOR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; CARBOXYLIC ACIDS; ESTERS; HIV; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MALE; METABOLIC CLEARANCE RATE; NAPHTHYRIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65649126737     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801404b     Document Type: Article

References (26)

1. Sweeney, Z. K.; Klumpp, K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr. Opin. Drug Discovery Dev. 2008, 11, 458-470.
2. von Hentig, N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today 2008, 44, 103-132.
3. Manfredi, R.; Sabbatani, S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr. Med. Chem. 2006, 13, 2369-2384. (Pubitemid 44184643)
4. MacArthur, R. D.; Novak, R. M. Maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 2008, 47, 236-241.
5. Pace, P.; Rowley, M. Integrase inhibitors for the treatment of HIV infection. Curr. Opin. Drug Discovery Dev. 2008, 11, 471-479.
6. Billich, A. S-1360 (Shionogi-GlaxoSmithKline). Curr. Opin. Invest. Drugs 2003, 4, 206-209.
7. (a) Anthony, N. J.; Gomez, R. P.; Young, S. D.; Egbertson, M.; Wai, J. S.; Zhuang, L.; Embrey, M.; Tran, L.; Melamed, J. Y.; Langford, H. M.; Guare, J. P.; Fisher, T. E.; Jolly, S. M.; Kuo, M. S.; Perlow, D. S.; Bennett, J. J.; Funk, T. W. Preparation of (Poly)azanaphthalenyl carboxamides as HIV Integrase Inhibitors. Patent WO 2002/030930 A2, 2002; Chem. Abstr. 2002, 136, 325531.
8. (b) Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, J. P., Jr.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth, A. S.; Jin, L.; Chen, I.-W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11233-11238. (Pubitemid 39038330)
9. Sorbera, L. A.; Serradell, N. GS-9137: anti-HIV agent HIV integrase inhibitor. Drugs Future 2006, 31, 310-313. (Pubitemid 43909813)
10. Cabrera, C. Raltegravir, an HIV-1 integrase inhibitor for HIV infection. Curr. Opin. Invest. Drugs 2008, 9, 885-898.
11. Chen, X.; Tsiang, M.; Yu, F.; Hung, M.; Jones, G. S.; Zeynalzadegan, A.; Qi, X.; Jin, H.; Kim, C. U.; Swaminathan, S.; Chen, J. M. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J. Mol. Biol. 2008, 380, 504-519.
12. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem. 2006, 14, 8420-8429. (Pubitemid 44667542)
13. Ferro, S.; De Luca, L.; Barreca, M. L.; Iraci, N.; De Grazia, S.; Christ, F.; Witvrouw, M.; Debyser, Z.; Chimirri, A. Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions. J. Med. Chem. 2009, 52, 569-573.
14. Johns, B. A.; Svolto, A. C. Advances in two-metal chelation inhibitors of HIV integrase. Expert Opin. Ther. Pat. 2008, 18, 1225-1237.
15. (a) Fuji, M.; Mikamiyama, H.; Murai, H. Preparation of Nitrogen-Containing Heteroaryl Compounds Having HIV Integrase Inhibitory Activity. Patent WO 2002/070486 A1, 2002; Chem. Abstr. 2002, 137, 232650.
16. (b) Murai, H.; Endo, T.; Kurose, N.; Taishi, T.; Yoshida, H. Preparation of Quinoline and Naphthyridine Derivatives as HIV Integrase Inhibitors. Patent WO 2004/024693 A1, 2004; Chem. Abstr. 2004, 140, 287278.
17. Taishi, T.; Tada, Y. Preparation of Diazanaphthalene Derivatives as HIV Integrase Inhibitors. Patent WO 2005/075475 A1, 2005; Chem. Abstr. 2005, 143, 211891.
18. Jeffery, T. Palladium-catalysed vinylation of organic halides under solid-liquid phase transfer conditions. J. Chem. Soc., Chem. Commun. 1984, 1287-1289.
19. Bajgrowicz, J. A.; Berg-Schultz, K.; Brunner, G. Structure-odor relationship of substituted hepta-1,6-dien-3-ones with green fruity odors. Bioorg. Med. Chem. 2003, 11, 2931-2946. (Pubitemid 36683012)
20. Isobe, K.; Mohri, C.; Sano, H.; Mohri, K.; Enomoto, H.; Sano, T.; Tsuda, Y. Dioxopyrrolines. XLIII. Diels-Alder reaction of 4,5-bis(ethoxycarbonyl)-1H- pyrrole-2,3-dione with butadienes: synthesis of polyfunctionalized hydroindoles. Chem. Pharm. Bull. 1989, 37, 3236-3238. (Pubitemid 20126526)
21. Ashcroft, W. R.; Beal, M. G.; Joule, J. A. Synthesis of the pyridine analogs of phthalide. J. Chem Soc., Perkin Trans. 1 1981, 3012-3015.
22. Bonnefous, C.; Vernier, J.-M.; Hutchinson, J. H.; Chung, J.; Reyes-Manalo, G.; Kamenecka, T. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 1197-1200. (Pubitemid 40458673)
23. Boros, E. E.; Burova, S. A.; Erickson, G. A.; Johns, B. A.; Koble, C. S.; Kurose, N.; Sharp, M. J.; Tabet, E. A.; Thompson, J. B.; Toczko, M. A. A scalable synthesis of methyl 3-amino-5-(4-fluorobenzyl)-2-pyridinecarboxylate. Org. Process Res. Dev. 2007, 11, 899-902.
24. The metal-binding mode of the title compounds is also reversed with respect to N-benzylhydroxynaphthyridinonecarboxamides. For examples, see the following: Egbertson, M.; Melamed, J. Y.; Langford, H. M.; Young, S. D. Preparation of Hydroxynaphthyridinone Carboxamides Useful as HIV Integrase Inhibitors. Patent WO 03062204, 2003; Chem. Abstr. 2003, 139, 133554.
25. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10, 1093-1095. (Pubitemid 23211439)
26. Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 2008, 52, 901-908.